KCM
TPST icon

Kingdon Capital Management’s Tempest Therapeutics TPST Stock Holding History

Kingdon Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-68
Closed -$1.7M – 143
2015
Q3 		$1.7M Sell
68
-161
-70% -$10.8M 0.08% 110
2015
Q2 		$19.4M Buy
229
+195
+574% +$17.9M 0.76% 43
2015
Q1 		$3.47M Buy
+34
New +$4.53M 0.15% 126

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OH
Orbis Holdings Hamilton, Bermuda $12.8B AUM 8.29% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kingdon Capital Management's TPST Position: Q3 2015 in Review

Kingdon Capital Management sold out of Tempest Therapeutics (TPST) in Q3 2015, closing a stake of 231 shares — an estimated $15.6M sold.

Kingdon Capital Management first reported a position in TPST in Q1 2014 and held it in 6 quarters. The position peaked at $27.1M in Q1 2015. 90 funds tracked by Wall St. Rank hold TPST as of Q3 2015.

  • Kingdon Capital Management reported no remaining Tempest Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Kingdon Capital Management sold 231 Tempest Therapeutics shares in Q3 2015, an estimated $15.6M.
  • Kingdon Capital Management first reported a position in Tempest Therapeutics in Q1 2014 and held it in 6 quarters.
  • Kingdon Capital Management's Tempest Therapeutics position peaked at $27.1M in Q1 2015.
  • 90 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2015.

Based on Kingdon Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.